PDS Biotechnology (PDSB) investor relations material

Company overview and business model

• Clinical-stage immunotherapy company focused on targeted cancer and infectious disease therapies using proprietary Versamune® and Infectimune® T cell activators, and PDS01ADC, an IL-12 antibody drug conjugate.

• Versamune® and Infectimune® platforms aim to induce potent, disease-specific T cell and antibody responses for oncology and vaccine applications.

• Proprietary combinations are being developed for use with immune checkpoint inhibitors and other standards of care to enhance cancer treatment efficacy.

Financial performance and metrics

• Entered into a Securities Purchase Agreement on April 30, 2026, issuing a $6,000,000 promissory note and a warrant for 2,158,274 shares, with a 4% original issue discount, for a total purchase price of $5,760,000.

• Promissory note bears 10% annual interest, payable monthly, and matures 12 months after the closing date.

Use of proceeds and capital allocation

• Will not receive proceeds from resale of shares by the selling stockholder; proceeds from any cash exercise of the warrant will be used for general corporate purposes.

• Selling stockholder pays commissions and discounts; company bears registration and listing costs.